Page 66 - Human Use News Today

Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "Global Vaccine Contract Manufacturing Market 2023-2028 by Function, Type, Applications, and Geography,...

Ipsen drug Bylvay is now FDA approved for treating pruritus, or severe itching, which is a complication of the rare liver disease Alagille syndrome. The oral drug was previously approved for treating pruritus in another rare inherited liver disease called PFIC.

– 6 Oral Presentations and 28 Posters Across HDV, HCV, HBV, NASH and PSC Highlight Progress and Gilead’s Leadership in Addressing Unmet Needs for People Affected by Liver Disease... | June 14, 2023

Approval heralds the second rare cholestatic liver disease indication for Bylvay in the U.S. after progressive familial intrahepatic cholestasis related pruritus in 2021 Immediate U.S. commercial... | June 13, 2023

Here, Dave Elder explores proposals for new FDA rules on tobacco product manufacturing and the concerns around tobacco-specific nitrosamines.

Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for ‘Arexvy’ - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

06.06.2023 - Pedmarqsi is the First and Only Approved Therapy in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid TumorsRESEARCH TRIANGLE PARK, N.C., June 06, ... Seite 1

E6(R3) GOOD CLINICAL PRACTICE (GCP)

Somapacitan (Sogroya, Novo Nordisk) injections are indicated to replace endogenous growth hormone in children with growth hormone deficiency.

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...